https://www.selleckchem.com/pr....oducts/acetalax-oxyp
In the therapeutic study, 12 patients were evaluable for toxicity, and 9 were evaluable for response. Among these, median follow-up was 3.5months, and best overall response was stable disease in 5 patients and progression of disease in 4 patients. Median progression-free survival was 1.8months. The most common treatment-related adverse events (grade2) were anemia, dyspnea, and hyperbilirubinemia. All patients had anemia (grades 1-3), with 33% having at least 1 dose reduction. Oral ribavirin decreases p-eIF4E l
Like
Comment
Share
